Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Mehmet Asim Bilen"'
Autor:
Greta Russler, Bassel Nazha, Sarah Caulfield, Mehmet Asim Bilen, Yuan Liu, Bradley C. Carthon, Sean Evans, Wayne Harris, Omer Kucuk, Jacqueline T. Brown, Viraj A. Master, Jamie M. Goldman, Dylan J. Martini, Lauren Yantorni, Ogul E. Uner, T. Anders Olsen, Julie M. Shabto
Publikováno v:
Clin Genitourin Cancer
Background : Full dose cabozantinib for metastatic renal cell carcinoma (mRCC) is 60mg, but adverse events (AEs) may require dose reductions. Limited data exist comparing efficacy among cabozantinib doses. We compared AEs and clinical outcomes in mRC
Autor:
Paul B. Robbins, Elaine T. Lam, Mehmet Asim Bilen, James Larkin, Alessandra di Pietro, Aly-Khan A. Lalani, Lance C. Pagliaro, Toni K. Choueiri, John B. A. G. Haanen, Eric Voog, Bradley Alexander McGregor, Nikolay Kislov, Bo Huang, Laurence Albiges, Stan Krulewicz, Brian I. Rini, Martin H. Voss
Publikováno v:
Clinical Cancer Research. 28:738-747
Purpose: To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib. Experimental Design: Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component,
Autor:
Dattatraya Patil, Vikram M. Narayan, Reza Nabavizadeh, Milton Williams, Dylan J. Martini, Kenneth Ogan, Shreyas S. Joshi, Sean Steele, Michelle I. Higgins, Viraj A. Master, Aarti Sekhar, Mehmet Asim Bilen, Sarah P. Psutka
Publikováno v:
Cancer. 127:1974-1983
Background Body composition and inflammation are gaining importance for prognostication in cancer. This study investigated the individual and combined utility of the preoperative skeletal muscle index (SMI) and the modified Glasgow Prognostic Score (
Autor:
Toni K. Choueiri, Amin Nassar, Pier Vitale Nuzzo, Marina D. Kaymakcalan, David A. Braun, Mehmet Asim Bilen, Sarah Abou-Alaiwi, Dylan J. Martini, John A. Steinharter, Ziad Bakouny, Justin H. Fleischer, Aly-Khan A. Lalani, Xiao X. Wei, Wanling Xie, Bradley Alexander McGregor, Lauren C. Harshman
Publikováno v:
European Journal of Cancer. 135:203-210
Background Cabozantinib is approved for the first and subsequent line treatment of metastatic clear-cell renal cell carcinoma (ccRCC) based on trials in which most patients were immune checkpoint blockade (ICB) naive. With an expanding role of ICB in
Publikováno v:
Kidney Cancer. 4:93-102
About one-third of advanced renal cell carcinoma (RCC) patients have bone metastases, which subsequently leads to the development of skeletal-related events (SREs), broadly defined to include surgery and radiation to bone, bone pain, pathological fra
Autor:
Mehmet Asim Bilen, Yuan Liu, Sarah Caulfield, Julie M. Shabto, Bradley C. Carthon, Viraj A. Master, Wayne Harris, Omer Kucuk, Dylan J. Martini, Haydn T. Kissick, Greta Russler, Emilie Elise Hitron
Publikováno v:
The Oncologist
Background The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria are the gold standard for risk‐stratifying patients with metastatic renal cell cancer (mRCC). We developed a novel risk scoring system for patients wit
Publikováno v:
Kidney Cancer
Papillary renal cell carcinoma (PRCC) is a subtype of renal cell carcinoma (RCC) accounting for approximately 15–20% of cases and further divided into Type 1 and Type 2. Type 1 PRCC tends to have more alterations in the MET tyrosine kinase receptor
Publikováno v:
Cancers, Vol 13, Iss 5065, p 5065 (2021)
Cancers
Cancers
Simple Summary Genitourinary malignancies include cancers along the urinary tract and the male reproductive tract, encompassing the adrenal glands, kidneys, bladder, prostate, and testicles. Immunotherapy, which treats cancer by using the immune syst
Autor:
Dylan J. Martini, T. Anders Olsen, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Bassel Nazha, Haydn T. Kissick, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
BackgroundImmune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). Biomarkers for mRCC patients treated with ICI are limited, and body composition is underutilized in mRCC. We investigated the as
Autor:
Wayne Harris, Bradley C. Carthon, Shreyas S. Joshi, Julie M. Shabto, Deepak Ravindranathan, Jacqueline T. Brown, Omer Kucuk, Sarah Caulfield, Kenneth Ogan, Dylan J. Martini, Viraj A. Master, Haydn T. Kissick, Lauren Yantorni, Emilie Elise Hitron, Mehmet Asim Bilen, Yuan Liu, Greta Russler, Bassel Nazha
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
BackgroundThe modified Glasgow Prognostic Score (mGPS) is a composite biomarker that uses albumin and C reactive protein (CRP). There are multiple immune checkpoint inhibitor (ICI)-based combinations approved for metastatic renal cell carcinoma (mRCC